Diala El-Maouche1, Samira M Sadowski1, Georgios Z Papadakis1, Lori Guthrie1, Candice Cottle-Delisle1, Roxanne Merkel1, Corina Millo1, Clara C Chen1, Electron Kebebew1, Michael T Collins1. 1. Division of Endocrinology (D.E.-M.), Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida; Skeletal Clinical Studies Unit (D.E.-M., L.G., M.T.C.), Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland; Thoracic and Endocrine Surgery (S.M.S.), University Hospitals of Geneva, Geneva, Switzerland; The Endocrine Oncology Branch (S.M.S., C.C.-D., R.M., E.K.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Positron Emission Tomography Department (G.Z.P., C.M.), Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, Maryland; Nuclear Medicine Division (C.C.C.), Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Abstract
CONTEXT: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. OBJECTIVE: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). DESIGN: This was a single-center prospective study of patients with TIO. SETTING: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. SUBJECTS: Eleven subjects (six females, five males) with TIO were included. INTERVENTION: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide single-photon emission CT (Octreoscan- SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. MAIN OUTCOME MEASURES: Localization of PMTs on the previously described imaging modalities were determined. RESULTS: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. CONCLUSIONS: In this first prospective study comparing 68Ga-DOTATATE PET/CT to Octreoscan-SPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.
CONTEXT: Phosphaturic mesenchymal tumors (PMTs) are small, typically difficult to localize, and express somatostatin receptors. Recent work suggests imaging studies using 68Gallium (68Ga)-conjugated somatostatin peptide analogues, such as 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)TATE, which enables somatostatin receptor imaging with positron emission tomography (PET), may be useful at identifying these tumors. OBJECTIVE: Our objective was to evaluate the use of 68Ga-DOTATATE PET/computed tomography (CT) for tumor localization in tumor-induced osteomalacia (TIO). DESIGN: This was a single-center prospective study of patients with TIO. SETTING: The study was conducted at the National Institutes of Health Clinical Center between February 2014 and February 2015. SUBJECTS: Eleven subjects (six females, five males) with TIO were included. INTERVENTION: Subjects underwent 68Ga-DOTATATE PET/CT in addition to 111In-pentetreotide single-photon emission CT (Octreoscan- SPECT/CT) and fluorodeoxyglucose-PET/CT (18F FDG-PET/CT) scan. MAIN OUTCOME MEASURES: Localization of PMTs on the previously described imaging modalities were determined. RESULTS: The tumor was successfully localized in 6/11 (54.5%) subjects (one was metastatic). The tumor was identified by 68Ga-DOTATATE in all six cases. Both Octreoscan-SPECT/CT and 18F FDG-PET each identified the tumor in 4/6. In no cases was 68Ga-DOTATATE the only imaging study to identify the tumor. CONCLUSIONS: In this first prospective study comparing 68Ga-DOTATATE PET/CT to Octreoscan-SPECT/CT and 18F FDG-PET in TIO localization, 68Ga-DOTATATE PET/CT demonstrated the greatest sensitivity and specificity, suggesting that it may be the best single study for localization of PMTs in TIO.
Authors: Simone U Dalm; Julie Nonnekens; Gabriela N Doeswijk; Erik de Blois; Dik C van Gent; Mark W Konijnenberg; Marion de Jong Journal: J Nucl Med Date: 2015-10-29 Impact factor: 10.057
Authors: Eric Hesse; Eckart Moessinger; Herbert Rosenthal; Florian Laenger; Georg Brabant; Thorsten Petrich; Klaus F Gratz; Leonard Bastian Journal: J Bone Miner Res Date: 2007-01 Impact factor: 6.741
Authors: Charles M Intenzo; Serge Jabbour; Henry C Lin; Jeffrey L Miller; Sung M Kim; David M Capuzzi; Edith P Mitchell Journal: Radiographics Date: 2007 Sep-Oct Impact factor: 5.333
Authors: G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano Journal: Osteoporos Int Date: 2017-03-25 Impact factor: 4.507
Authors: Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins Journal: Calcif Tissue Int Date: 2020-06-05 Impact factor: 4.333
Authors: Lulu Sun; Carina Dehner; Jason Kenney; Samantha M McNulty; Xiaopei Zhu; John D Pfeifer; Horacio M Maluf; John S A Chrisinger Journal: Virchows Arch Date: 2020-11-05 Impact factor: 4.064